N/A
Completed N=28
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Source: ClinicalTrials.gov NCT01215123 ↗Enrolled (actual)
28
Serious AEs
35.7%
Results posted
Feb 2016
Primary outcomePrimary: Time to Disease Progression (TDP) — 15.3 months
Summary
This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Disease Progression (TDP) |
15.3 | — |
| SECONDARY Treatment Duration: Number of Bevacizumab Cycles |
6 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin
Exclusion Criteria
- Patients not willing or unable to signed written consent form
Data sourced from ClinicalTrials.gov (NCT01215123). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.